EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments
2y agoen
From the article
GSK has announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin.
Continue reading on GSKYou might also wanna read

How Insurers Use Copay Accumulator Programs to Undermine Drug Assistance for Patients
This article investigates how health insurers use "copay accumulator" programs to prevent drug manufacturer copay assistance coupons from co

Vets issue urgent warning to pet owners as flesh-eating screwworm spreads through Texas and New Mexico
FORTUNE·7h ago

Australia news live: Telstra warns of ‘secondary issue’ after yesterday’s network outage; trains in regional Victoria cancelled again
The Guardian·8h ago
ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee
pharmaphorum·9h ago
UPMC returns to profitability with $380M profit after two years of losses
UPMC returned to profitability in fiscal year 2024-2025 with a profit of over $380 million, reversing two years of historically large losses
How Front-Desk Friction Drives Patient Churn Despite High Clinical Satisfaction
A primary-care patient rated her physician highly but left the practice due to poor front-desk experiences — specifically, long phone wait t

Comments
Sign in to join the conversation.
No comments yet. Be the first.